Search
Nebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigationalNebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. … [A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: NEBIVOLOL AL 5MG TABLAvelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: BAVENCIO 200 MG/10 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 FLAKONOxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigational[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. … Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin.
Categories: OCT2 Substrates with a Narrow Therapeutic IndexProducts: AL OXA ® SOLUCION CONCENTRADA PARA INFUSION, OXALIPLATINO SANDOZ BVCytarabine
go.drugbank.com/drugs/DB00987ApprovedInvestigationalA pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. … Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: Aj-cytarabine, ALDACIT® 500 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLEFluticasone propionate
go.drugbank.com/drugs/DB00588ApprovedInvestigationalFluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. … These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].
Mixtures: FLUSARION EH50/250UG/60 PC, FLUSARION EH50/500UG/60 PCCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesBeta carotene
go.drugbank.com/drugs/DB06755ApprovedNutraceuticalIt is an antioxidant that can be found in yellow, orange and green leafy vegetables and fruits.[T158] Under the FDA, beta-carotene is considered as a generally recognized as safe substance (GRAS). … [T162] It is the most abundant form of carotenoid and it is a precursor of the vitamin A. Beta-carotene is composed of two retinyl groups.
Mixtures: Virt-Pn, PR Natal 430Categories: Vitamin A, Protectives Against UV-RadiationLacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigationalLacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. … Lacosamide exhibits a stereoselective mode of interaction with sodium channels.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Ag-lacosamide, BENVIDA 10 MG/ML IV INFUZYON COZELTISI, 20 MLAntihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Mixtures: HAEMATE P, HAEMATE PCategories: Hemophilia AGuaifenesin
go.drugbank.com/drugs/DB00874ApprovedInvestigationalVet approvedused as an expectorant [F4525]. … an NMDA receptor antagonist [A177652].
Mixtures: Panto A, Tukol AProducts: GUAYACOLATO DE GLICERILO JARABE AL 2%Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigationalPolycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for … [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2A6 InhibitorsSynonyms: PEG-P-IFN-alfa-2b, PEG-P-IFN-alpha-2b